Modern methods of contraception by Githiari, J
Malawi Medical JoumaI. March 1993. Vol. 9. No. 1 13 
SESSION TWO: CONTRACEPTIVE METHODS 
Modern Methods of Contraception 
Dr. J. Githiari 
Introduction 
like most ideas which seem very new, fertility control is in 
fact very old. It was mentioned in an ancient Egyptian papyrus 
written 4,000 years ago and was a topic of lively discussions 
among Greek philosophers at least 2,400 years ago 1. The urge 
to limit family size appears to be almost as old as mankind itself. 
Presumably the first men and women to practice fertility 
control had the same motive as do many couples today; they 
wanted to be relieved of the constant confinement of preg-
nancy, and the burden of properly feeding and caring for a new 
baby each year. 
In modern societies fertility control is needed for reducing 
the estimated 500,000 maternal deaths related to child birth 
which occur each year. Most of these deaths occur in the 
developing world where maternal mortality is about 300-1,000 
per 100,000 live births as compared to 2-9 per 100,000 live births 
in the developed world 2. 
The early methods offertility control were, of course, primi-
tive and not very effecrive, as they remain today in parts of the 
world where modern contraceptive l~ethods have not been 
introduced. These methods included the use of charms, herbs, 
roots, teas, seeds and others. For example in Egypt eating the 
seeds of the castor oil plant the day after child birth was thought 
to provide a one-year protection against pregnancy. 
As we know now, the search for some substance which could 
be taken by mouth by a woman to prevent unwanted pregnancy 
eventually became successful in 1955 when the pill was formu-
lated following extensive research, experiments and toxicologi-
cal studies. Modern scientific research has also lead to the 
introduction of other contraceptive methods including inject-
ables, Norplant implants, intrauterine contraceptive devices 
(IUCD), condoms, cervical caps, diaphragm, spermicides, natu-
ral methods (coitus interruptus, abstinence, symptom-thermal), 
and the voluntary surgical contraception. 
Efficacy and Safety of contraceptives 
The modern contraceptive methods are fairly safe and very 
effective when used correctly. One of the goals of the Birth 
Control Investigation Committee (BCIC) which was established 
in 1927 was to ensure quality of contraceptive products being 
offered in the market. The BCIC developed laboratory tech-
niques for the assay of vaginal contraceptives, elaborate statisti-
cal formulae for the measurement of contraceptive efficacy and 
developed new spermicides. The BCIC established the Popula-
tion Investigation Committee which publishes the international 
Journal Population Studies. 
The vaginal spermicides must be non-toxic and non-irritant 
to the vagina and must be effective in immobilizing sperms. 
Rubber products are used extensively in the production of 
condoms, caps and diaphragms. The properties of these appli-
ances as well as the effect upon them of storage, lubricants and 
chemical spermicides are of considerable significance. The plas-
tic which forms the body of the IUCDs must be of a high and 
uniform quality to prevent fragmentation ofthe IUCD in utero. 
The quality of piIIs and injectables which are systemically active 
is essential and samples from a production line are regularly 
tested for hormonal assay, tablet strength and bacteriological 
sterility for parenteral medications. 
Effectiveness 
The theoretical or biological effectiveness of a method meas-
ures the pregnancy rate experienced when the method is used 
in ideal conditions and excludes pregnancies that are due to 
failure to use the method or to errors in its use. This differs from 
the use-effectiveness which measures the pregnancy rate when 
the method is used under real-life conditions and includes 
failures due to error in its use. 
The use-effectiveness of a method is the failure rate per 100 
woman-years of exposure. The basis for calculating this failure 
rate is the Pearl Pregnancy rate which is expressed as: 
Failure rate per HWY = Total accidental pregnancies X 1200 
Total months of exposure 
ORAL CONTRACEPTIVES 
In 1952 the orally active progestagens norethynodrel and 
norethisterone and mestranol which has oestrogenic effects 
became commercially available. These steroids paved the way 
for the formulation of the "combined" pill which first appeared 
about 1960. In the combined pill a progestogen is combined 
with an orally active oestrogen (mestranol or ethyniloestradiol) 
in varying doses. The most commonly used combined pills in 
Africa are the combined preparations of ethynodiol diacatate 
and ethyniloestradiol. 
The dose of the combined pills has fallen dramatically from 
a high of 10 mg of progestogen per tablet (OrthoNovum, 1962) 
to 1 mg in many contemporary preparations and from 1 mg of 
oestrogen (Enavid, 1964) to as little as 0.02 mg. Improvements 
in oral contraceptives since 1960 have been in the direction of 
loweling the dose. 
The minipill or the progestogen only pill is poorly accepted 
mainly because ofits reduced contraceptive effect and irregular 
bleeding. 
Mode of action 
The pill inhibits ovulation by a direct oestrogenic effect on 
the hypothalamus, resulting in pituitary suppression. There is 
no mid cycle increase in oestrogen, follicular stimulating hor-
mone (FSH), and the pre-ovulatory luteinizing hormone (LH) 
sJ.trge does not occur. The progestogen also makes the cervical 
mucus hostile and impervious to spermatozoa. 
Effectiveness 
The theoretical effectiveness of the pill is almost 100%. The 
use-effectiveness, however, is about 0.34 pregnancies per 100 
woman years. 
Systemic effects 
The steroids contained in the oral pills have various systemic 
effects which include cardiovascular changes, changed carbohy-
drate metabolism, alterations of the liver functions and in-
creased tendency of blood clotting system. Because of these 
changes clients who request oral pills must be screened to 
exclude pre-existing diseases in these areas. 
Side effects 
During the first three months of use clients may experience 
nausea, vomiting, breast tenderness, weight gain, fluid reten-
tion, headaches, initability and loss of libido. The combined 
oral contraceptives reduce the volume of breast milk as well as 
its constituents. It is therefore not recommended for breast 
feeding mothers. 
Contraindications 
Absolute contraindications include thromboembolic disor-
ders, cerebrovascular and coronary diseases, impaired liver 
function and hepatic adenoma, tumours of the reproductive 











































dications are over 35 years of age, undiagnosed vaginal bleed-
ing, diabetes and severe headaches. 
r 
NORPLANT 
Norplant is an effective, long-acting reversible contracep-
tive that provides protection for 5 years. The system consists 
of six flexible silastic capsules. Each capsule is 34 mm long, 
with a diameter of 2.4 mm, and contains 36 mg of levonor-
gestrel. The capsules are inserted just under the skin in the 
upper arm. Levonorgestrel diffuses through the silastic mem-
brane at a steady, slow rate. Within 24 hours after insertion, 
levels of levonorgestrel in the blood plasma are high enough 
to prevent ovulation. The daily release averages 50-80 micro-
grams per day over next five years. In the first year, this is 
about the same as the daily dose of levonorgestrel in pro-
gestin-only piD and about 0.2!HL5 of the dose in combined 
pills. . 
Effectiveness 
Norplant is very effective and provides almost complete 
protection. The chances of pregnancy are less than one per 100 
women per year, which is lower than for oral pills, IUCD and 
barrier method~. 
Heavier women over 70 kg have a higher failure rate than 
lighter women after the second year. Effectiveness decrease 
after 5 years and in the sixth year about 30% of users will 
conceive. Thus replacement after 5 years is recommended. A 
slight and gradual decrease in the daily release oflevonorgestrel 
over time probably accounts for the increase in pregnancy after 
5 years. ( 
Mode of action 
Precisely how Norplant prevents pregnancy is not fully un-
derstood, but like the other progestin-only contraceptives, prob-
ably it works through several ways. Norplant suppresses 
ovulation in 50% menstrual cycles. Even if ovulation occurs in 
the remaining cycles, levonorgestrel makes cervical mucus thick 
and scanty which hinders sperm transportation into the uterus. 
Levonorgestrel also suppresses the cyclic endometrial develop-
ment in 50% of the users. 
ContraindicatioD8 
Norplant may be used by almost any woman in her fertile 
years who wants to space births for up to 5 years. However, 
because of the systemic effects of levonorgestrel thromboem-
bolic disorders, undiagnosed genital bleeding, acute liver dis-
ease, tumours of the liver and cancer of the breast are medical 
contraindications for this method. These are in addition to the 
traditionally accepted contraindications for hormonal contra-
ceptives including pregnancy, pregnancy hepatosis and hor-
mone dependent cancers. 
INTRAUTERINE DEVICES (ruCD) 
It. is not fully understood how IUCDs act, but the most 
commonly accepted mechanism of action oflUCDs inv<llves the 
foreign body reaction which occurs in the uterine cavity follow-
ing IUCD insertion. When IUCD is introduced in the uterine 
cavity biochemical changes and cellular reaction take place 
which is characterized by increased vascular permeability, oe-
dema, infiltration of leukocytes and production of pro-
staglandin. 
Addition of copper to the mCD produces increased mor-
phological changes, affects endometrial enzymes, glycogen me-
tabolism and oestrogen uptake by the uterine mucosa. Steroids 
added to the mCDs suppress proliferation of glands and in-
crease decidual transformation of the stroma. 
The changed uterine environment interferes with sperm 
transportation and is also hostile to implantation. High levels of 
prostaglandin increase tubal motility which may interfere with 
ovum transportation !I These changes combine together to 
provide the contraceptive effect of the IUCD. 
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Types of ruCDs 
There main two types of IUCDs: the inert or non-medicated 
mCDs and the biologically active or medicated mCDs. The 
non-medicated mCD commonly used in AfriCa is the Lippes 
loop, but this device is no longer in production. 
The medicated IUCDs include the copper-bearing devices 
Cu T 380 A, Cu T 200 and the multiload. The Cu T 380 A is the 
same size and shape as the Cu T 200, but has small copper bands 
on both arms of the T thus increasing the exposed surface area 
of 380 mm sq. of copper. This extra copper increases the 
contraceptive effectiveness of the device. The copper IUCDs 
have been approved for use up to 8 years. 
Hormone-releasing IUCDs constantly release small amounts 
of steroid hormone into the uterus. Progestasert, the ouly 
available hormone-releasing IUCD contains 38 mg progester-
one and release 65 micrograms per day. The device is active for 
one year. 
IUCDs are commonly inserted six weeks after completion 
of a pregnancy, but recent studies have shown that the 
IUCDs may also be inserted after non-septic abortion, after 
delivery of the placenta or at the caesarean section. The 
providers skills and experience are very important in reduc-
ing expulsions and other complications of postpartum IUCD 
insertion. 
Effectiveness and complications 
The IUCD is one of the most effective contraceptive meth-
ods. Most devices h.ave a pregnancy rate of 1-3 per 100 women 
per year. The pregnancy rate for the new Cu T devices is less 
than I per 100 women per year 4. 
Possible complications of IUCDs use include perforation 
usually during insertion, increaseo risk of infection, bleeding, 
pelvic pain, expulsion and ectopic or intrauterine pregnancy. 
Most of these complications can be reduced if providers are 
well trained. 
INJECTABLE CONTRACEPTIVES 
The two formulations available for parenteral ~ntraceptive 
use are Depot medroxy progesterone acetate -tOepo Provera, 
DMPA) and Norethisterone enanthate (Noristerat). Depo pro-
vera is more widely used in Africa. 
150 mg ofDMPA is given as intramuscular injection every 3 
months. Pregnancy rates have been comparable to those re-
ported with oral contraceptives, ranging from 1.0 to 1.2 per 100 
woman-years 5. 
Mode of Action 
Injectables act primarily by inhibiting ovulation. Levels of 
FSH and LH are lowered, and the LH surges do not occur. 
Pituitary response to exogenous gonadotrophin-releasing hor-
mone remains intact, suggesting a hypothalamic rather than 
pituitary site of action. 
In addition DMPA has other anti-fertility effects on the 
reproductive system which enhance its contraceptive action. 
The endometrium becomes shallow and atrophic with inactive 
glands, the stroma becomes oedematous and decidualized, the 
sperm penetration of tile cervical mucous is decreased and the 
motility of the fallopian tubes is decreased. 
Side Effects 
The main medical problems of tile injectable contraceptives 
include unpredictable bleeding pattern, weight increase and 
subjective complaints of headaches, dizziness, abdominal dis-
comfort, fatigue and sometimes nausea. 
Weight increase is considered to be associated with increased 
fat deposition, which may simply be due to increased appetite 
and food intake. 
The unpredictable bleeding pattern is the major drawback 
of this method. Polymenorrhea and prolonged bleeding and 
spotting are more frequent after the first injection and are 
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rhoea after 'repeated injections. A WHO multicentre study 
showed that the percentage of users with total amenorrhoea 
gradually increased from 13.4% after the first injection to 35% 
after four injections 5. 
The return of menstruation and fertility after discontinuing 
DMPA follows the return of ovulation. The return of ovulation 
and fenility is related to the persistence ofDMPA in the user's 
circulation. After a 150-mg injection ofDMPA, the mean inter-
val before ovulation returns is 4.5 months. In a large study 
comparing conception rates in women discontinuing various 
methods, conception was delayed in former DMPA users when 
compared with women discontinuing oral pills and IUCDs 
during the first 9 months following discontinuation. Almost 
70% ofDMPA users, however, had conceived within the first 12 
months following discontinuation 6. The delayed return of 
fertility has important implications for counselling candidates 
for injectable contraceptives. 
Injectable contraceptives appear safe for use immediately 
postpartum and have not been associated with problems of 
infant nutrition or development when used by lactating women 
6. Different studies have shown increased milk production, but 
no significant changes in the concentrations of lactose, protein 
or lipid. 
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Programme at Nkhoma Hospital 
Dr. N. van Velden, Dr. PJ. Blignaut 
For the last few years at Nkhoma Hospital we have been 
giving special attention to Child-Spacing and in particular 
to surgical contraception. With the help and encourage-
ment of the Association for Voluntary Surgical Contracep-
tion (AVSC) we increased the number of tubal ligations from 
54 in the first quarter of 1991 to 175 in the 4th quarter of 
1992. 
The most important part of the programme is the coun-
selling and selection of the patients. Because tubal ligation is 
a permanent procedure, the patient must be well informed 
and the spouse and parents must also be involved in the 
decision making. 
A VSC is an international organisation with its regional head-
quarters in Nairobi. They support any hospital that wants to 
participate in their programme. The support consists of training 
of staff, supplying equipment and reimbursement of expenses. 
In return they require that their technique is adhered to and 
any complications reported. A uniform consent form must be 
used and all counsellors and surgeons must attend one of their 
workshops. 
Tubal Ligations at Nkhoma Hospital 
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The Surgical Procedure 
15 
For women, this procedure can be done either after delivery 
(post partum tubal ligation) or on the non-pregnant uterus 
(interval tubal ligation). 
The post partum Tubal Ligation (TL) 
This is very easy to perform and has few complications. A 
small (1.5 - 2 cm) incision is made just under the umbilicus. 
Once the abdomen has been entered, the skin is manipulated 
with retractors until the tubes can be seen. A Pomeroy proce-
dure is done and the wound is closed. The patient goes home 
the same day. 
The Interval Tubal Ligation 
This needs a bit more skill but is easy to do once the 
technique is mastered. First, an uterine elevator is inserted 
into the uterus through the cervix (just as one would insert 
a IUCD). Later this will be used to bring the uterus in contact 
with the anterior abdominal wall and to manipulate it from 
side to side. The abdominal wall is now cleaned and draped. 
A small (2 - 5 cm) incision is made under local anaesthesia 
in the midline of the lower abdomen. Once the abdomen 
has been entered, the patient is put in the Trendlelen-
burg position. This, together with deep inspiration will help 
to move the bowel away from the pelvic organs. Now the 
uterine elevator is used to bring the tubes in sight near the 
incision. Again a Pomeroy Procedure is done and the wound 
closed. 
With both techniques the patient must be well informed and 
cooperative. Preferably the counsellor nurse should be present 
to calm and comfort the patient. 
Obesity, previous scars or infection and distended bowels 
make the procedure more difficult, but there are no absolute 
contra-indications. Complications of these procedures are 
bleeding, visceral injuries and infection. 
If the procedure cannot be completed under local anaes· 
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